Baker Bros. Advisors Adds $98K in Skye Bioscience, Inc. ($SKYE)
Key Points
- Baker Bros. Advisors changed its Skye Bioscience, Inc. ($SKYE) stake by 8.6% last quarter, boosting to 1,575,243 shares worth $1.24 million.
- $SKYE last traded around $0.79.
Baker Bros. Advisors increased its position in Skye Bioscience, Inc. ($SKYE) by 8.6% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,575,243 shares of Skye Bioscience, Inc. after buying 124,605 shares during the quarter. Baker Bros. Advisors's holdings in Skye Bioscience, Inc. were worth $1.24 million as of its most recent filing.
Skye Bioscience, Inc. ($SKYE) Stock
Skye Bioscience, Inc. Earnings
Analysts Set New Price Targets
About Skye Bioscience, Inc.
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.